

This listing of claims will replace all prior versions, and listings, of claims in the application:

### LISTING OF CLAIMS:

---

Claim 1. (previously presented): A method of treatment of a patient undergoing opioid analgesic therapy which comprises minimizing or mitigating the side effects of the opioid by the administration of a therapeutically effective amount of devazepide.

Claim 2. (previously presented): A method of treatment of a patient requiring analgesia which comprises the administration of a therapeutically effective amount of an opioid analgesic whilst minimising the side effects of the opioid by the separate, simultaneous or sequential administration of a therapeutically effective amount of devazepide.

Claim 3. (currently amended): A method according to claim 1 characterised characterized in that the ~~opioid analgesic~~ is selected from the group consisting of morphine, ~~or a salt thereof such as the sulphate, chloride or hydrochloride,~~ meperidine, pentazocine, dextromoramide, diphenoxylate, dipipanone, meptazinol, methadone, nalbuphine, phenadoxone, phenazocine, remifentanyl, tramadol, or the other a 1,4-hydroxymorphinan opioid analgesics such as ~~naloxone, meperidine, butorphanol, or pentazocine, or morphine 6 glucuronide, codeine, dihydrocodeine, diamorphine, dextropropoxyphene, pethidine, fentanyl, alfentanil, alphaprodine, buprenorphine, dextromoramide, diphenoxylate, dipipanone, heroin (diacetylmorphine), hydrocodone (dihydrocodeinone), hydromorphone (dihydromorphinone), levorphanol, meptazinol, methadone, metopon (methyldihydromorphinone), nalbuphine, oxycodone, (dihydrohydroxycodeinone), oxymorphone (dihydrohydroxymorphinone), phenadoxone, phenazocine, remifentanyl, tramadol,~~ or a salt of any of these the aforementioned, and combinations thereof.

Claim 4. (currently amended): A method according to claim 1 characterised characterized in that the ~~opioid analgesic~~ is selected from the group consisting of morphine, ~~or a salt thereof such as~~

~~the sulphate, chloride or hydrochloride, meperidine, pentazocine, dextromoramide, diphenoxylate, dipipanone, meptazinol, methadone, nalbuphine phenadoxone phenazocine, remifentanyl, tramadol~~, or the other a 1,4-hydroxymorphinan opioid analgesics such as naloxone, meperidine, butorphanol, or pentazocine, or morphine-6-glucuronide, codeine, dihydrocodeine, diamorphine, dextropropoxyphene, pethidine, fentanyl, alfentanil, alphaprodine, buprenorphine, dextromoramide, diphenoxylate, dipipanone, heroin (diacetylmorphine), hydrocodone (dihydrocodeinone), hydromorphone (dihydromorphinone), levorphanol, meptazinol, methadone, metopon (methyldihydromorphinone), nalbuphine, oxymorphone (dihydrohydroxymorphinone), tramadol, or a salt of any of these the forementioned, and combinations thereof.

Claim 5. (previously presented): A method according to claim 3 characterised in that the opioid is selected from the group hydromorphone, oxycodone, morphine and fentanyl.

Claim 6. (previously presented): A method according to claim 4 characterised in that the opioid is selected from the group hydromorphone, oxycodone, morphine and fentanyl.

Claim 7. (previously presented): A method according to claim 5 characterised in that the opioid is selected from the group morphine and morphine sulphate.

Claim 8. (previously presented): A method according to claim 6 characterised in that the opioid is selected from the group morphine and morphine sulphate.

Claim 9. (previously presented): A method according to claim 1 characterised in that the method of delivery of the devazepide and/or the opioid is selected from the group, administration intravenously, orally, intrathecally, intranasally, intrarectally, intramuscularly/subcutaneously, by inhalation and by transdermal patch.

Claim 10. (previously presented): A method according to claim 2 characterised in that the method of delivery of the devazepide and/or the opioid is selected from the group, administration

intravenously, orally, intrathecally, intranasally, intrarectally, intramuscularly/subcutaneously, by inhalation and by transdermal patch.

Claim 11. (previously presented): A method according to claim 9 characterised in that the devazepide is administered intravenously or orally.

Claim 12. (previously presented): A method according to claim 10 characterised in that the devazepide is administered intravenously or orally.

Claim 13. (previously presented): A method according to claim 11 characterised in that the devazepide is administered orally.

Claim 14. (previously presented): A method according to claim 12 characterised in that the devazepide is administered orally.

Claim 15. (previously presented): A method according to claim 9 characterised in that the opioid is administered intravenously and the devazepide is administered intravenously.

Claim 16. (previously presented): A method according to claim 10 characterised in that the opioid is administered intravenously and the devazepide is administered intravenously.

Claim 17. (previously presented): A method according to claim 9 characterised in that the opioid is administered orally and the devazepide is administered orally.

Claim 18. (previously presented): A method according to claim 10 characterised in that the opioid is administered orally and the devazepide is administered orally.

Claim 19. (previously presented): A method according to claim 9 characterised in that the opioid is administered by intravenous administration or oral administration.

Claim 20. (previously presented): A method according to claim 10 characterised in that the opioid is administered by intravenous administration or oral administration.

Claim 21. (previously presented): A method according to claim 1 characterised in that the daily dosage of devazepide is up to 0.7 mg/kg/day.

Claim 22. (previously presented): A method according to claim 2 characterised in that the daily dosage of devazepide is up to 0.7 mg/kg/day.

Claim 23. (previously presented): A method according to claims 21 characterised in that the daily dosage of devazepide is from 25 ug/kg/day to 0.7 mg/kg/day.

Claim 24. (previously presented): A method according to claims 22 characterised in that the daily dosage of devazepide is from 25 ug/kg/day to 0.7 mg/kg/day.

Claim 25. (previously presented): A method according to claim 23 characterised in that the daily dosage of devazepide is from 50 ug/kg/day to 0.5 mg/kg/day.

Claim 26. (previously presented): A method according to claim 24 characterised in that the daily dosage of devazepide is from 50 ug/kg/day to 0.5 mg/kg/day.

Claim 27. (previously presented): A method according to claim 25 characterised in that the devazepide is administered orally and the daily dosage of devazepide is from 0.07 mg/kg/day to 0.29 mg/kg/day.

Claim 28. (previously presented): A method according to claim 26 characterised in that the devazepide is administered orally and the daily dosage of devazepide is form 0.07 mg/kg/day to 0.29 mg/kg/day.

Claim 29. (previously presented): A method according to either of claims 25 characterised in that the devazepide is administered intravenously administration the dosage of devazepide is from 50 ug/kg/day to 0.5 mg/kg/day.

Claim 30. (previously presented): A method according to either of claims 26 characterised in that the devazepide is administered intravenously administration the dosage of devazepide is from 50 ug/kg/day to 0.5 mg/kg/day.

Claim 31. (previously presented): A method according to claim 1 characterised in that the daily dosage of the opioid is from 5 to 2000 mg daily.

Claim 32. (previously presented): A method according to claim 2 characterised in that the daily dosage of the opioid is from 5 to 2000mg daily.

Claim 33. (previously presented): A method according to claim 31 characterised in that the daily dosage of the opioid is from 5 to 100mg daily.

Claim 34. (previously presented): A method according to claim 32 characterised in that the daily dosage of the opioid is from 5 to 100mg daily.

Claim 35. (previously presented): A method according to claim 1 characterised in that the side effect which is inhibited, mitigated or minimised is selected from the group, constipation, dizziness, tiredness/fatigue and vomiting.

Claim 36. (previously presented): A method according to claim 2 characterised in that the side effect which is inhibited, mitigated or minimised is selected from the group, constipation, dizziness, tiredness/fatigue and vomiting.

Claim 37. (previously presented): A method according to claim 1 characterised in that the devazepide used is the S enantiomer wherein the level of R enantiomer is not greater than 1.5% w/w.

Claim 38. (previously presented): A method according to claim 2 characterised in that the devazepide used is the S enantiomer wherein the level of R enantiomer is not greater than 1.5% w/w.

Claim 39. (previously presented): The use of devazepide in the manufacture of a medicament which inhibits or mitigates the undesirable side effects of administration of a therapeutically effective amount of an opioid analgesic.

Claim 40. (previously presented): The use according to claim 39 characterised in that the devazepide used is the S enantiomer wherein the level of R enantiomer is not greater than 1.5% w/w.

Claim 41. (currently amended): The use of devazepide in the manufacture of a medicament for use in the method of either of claim 1.

Claim 42. (currently amended): The use of devazepide in the manufacture of a medicament for use in the method of either of claim 2.

Claim 43. (new): A method according to claim 3 wherein the morphine is a morphine salt selected from the group consisting of sulphate, chloride, and hydrochloride.

Claim 44. (new): A method according to claim 3 wherein the 1,4 hydroxymorphinan opioid analgesic is selected from the group consisting of butorphanol, morphine-6-glucuronide, codeine, dihydrocodeine, diamorphine, buprenorphine, heroin (diacetylmorphine), hydrocodone (dihydrocodeinone), hydromorphone (dihydromorphinone), levorphanol, metopon (methyldihydromorphinone), oxycodone (dihydrohydroxycodeinone), oxymorphone (dihydrohydroxymorphinone), a salt of any of the aforementioned, and combinations thereof.

Claim 45. (new): A method according to claim 4 wherein the morphine is a morphine salt selected from the group consisting of sulphate, chloride, and hydrochloride.

Claim 46. (new): A method according to claim 4 wherein the 1,4 hydroxymorphinan opioid analgesic is selected from the group consisting of butorphanol, morphine-6-glucuronide, codeine, dihydrocodeine, diamorphine, buprenorphine, heroin (diacetylmorphine), hydrocodone

(dihydrocodeinone), hydromorphone (dihydromorphinone), levorphanol, metopon  
(methyldihydromorphinone), oxycodone (dihydrohydroxycodeinone), oxymorphone  
(dihydrohydroxymorphinone), a salt of any of the aforementioned, and combinations thereof.

---